Anti-Coagulants - Brazil

Brazil

In Brazil, the Anti-Coagulants market is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is set to reach €0.55bn by 2024.
Furthermore, it is anticipated that the market will experience a compound annual growth rate (CAGR 2024-2029) of 8.32%, leading to a market volume of €0.82bn by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Coagulants market, with an estimated revenue of €15,520.00m in 2024.
Brazil is experiencing a growing demand for anti-coagulants as the aging population increases the prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Anti-Coagulants market in Brazil has been experiencing steady growth in recent years.

Customer preferences: There is a growing demand for Anti-Coagulants in Brazil due to an increase in the prevalence of cardiovascular diseases and strokes. Additionally, an aging population and changing lifestyles have contributed to the rise in demand for these medications.

Trends in the market: The Anti-Coagulants market in Brazil has been experiencing a shift towards newer oral anti-coagulants, which are more convenient for patients to take and have fewer side effects compared to traditional anti-coagulants. Additionally, there has been an increase in the number of patients being treated for non-valvular atrial fibrillation, which is driving growth in the market.

Local special circumstances: Brazil has a large population with a high prevalence of cardiovascular diseases, which has led to a significant demand for Anti-Coagulants. However, the market is highly regulated, which can make it difficult for new players to enter the market. Additionally, there is a lack of awareness among patients and healthcare professionals about the benefits of Anti-Coagulants, which can hinder growth in the market.

Underlying macroeconomic factors: The Brazilian economy has been recovering from a recession in recent years, which has led to an increase in healthcare spending. Additionally, the government has implemented policies to increase access to healthcare, which has led to an increase in the number of patients being treated for cardiovascular diseases. These underlying macroeconomic factors have contributed to the growth of the Anti-Coagulants market in Brazil.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.